Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 78
Filtrar
1.
Paediatr Respir Rev ; 45: 16-22, 2023 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-35534343

RESUMO

Chronic Kidney Disease (CKD) is characterized by a progressive and irreversible loss of kidney function which gradually leads to end-stage kidney disease (ESKD). Virtually all the organs are damaged by the toxicity of uremic compounds. The lungs may be affected and the impaired pulmonary function may be the direct result of fluid retention and metabolic, endocrine and cardiovascular alterations, as well as systemic activation of the inflammation. An increased prevalence in sleep disorders (SD) is also reported in patients with CKD, leading to a further negative impact on overall health and quality of life. While these complex relationships are well documented in the adult population, these aspects remain relatively little investigated in children. The aim of this review is to provide a brief overview of the pathophysiology between lung and kidney and to summarize how CKD may affect respiratory function and sleep in children.


Assuntos
Falência Renal Crônica , Insuficiência Renal Crônica , Transtornos do Sono-Vigília , Adulto , Humanos , Criança , Qualidade de Vida , Insuficiência Renal Crônica/complicações , Insuficiência Renal Crônica/epidemiologia , Falência Renal Crônica/complicações , Falência Renal Crônica/epidemiologia , Rim , Transtornos do Sono-Vigília/epidemiologia , Transtornos do Sono-Vigília/etiologia
2.
Nat Commun ; 13(1): 3677, 2022 06 27.
Artigo em Inglês | MEDLINE | ID: mdl-35760799

RESUMO

Retinal dystrophies such as Retinitis pigmentosa are among the most prevalent causes of inherited legal blindness, for which treatments are in demand. Retinal prostheses have been developed to stimulate the inner retinal network that, initially spared by degeneration, deteriorates in the late stages of the disease. We recently reported that conjugated polymer nanoparticles persistently rescue visual activities after a single subretinal injection in the Royal College of Surgeons rat model of Retinitis pigmentosa. Here we demonstrate that conjugated polymer nanoparticles can reinstate physiological signals at the cortical level and visually driven activities when microinjected in 10-months-old Royal College of Surgeons rats bearing fully light-insensitive retinas. The extent of visual restoration positively correlates with the nanoparticle density and hybrid contacts with second-order retinal neurons. The results establish the functional role of organic photovoltaic nanoparticles in restoring visual activities in fully degenerate retinas with intense inner retina rewiring, a stage of the disease in which patients are subjected to prosthetic interventions.


Assuntos
Nanopartículas , Retinose Pigmentar , Próteses Visuais , Animais , Modelos Animais de Doenças , Humanos , Polímeros , Ratos , Retinose Pigmentar/terapia
3.
Acta Neurol Scand ; 124(6): 417-23, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21649612

RESUMO

BACKGROUND: Tetracyclines could have neuroprotective effects in neuromuscular and neurodegenerative disorders. AIMS OF THE STUDY AND METHODS: Objective of this double-blind randomized pilot study (followed by an adjunctive open-label phase) was to evaluate whether tetracycline (500 mg/day × 14 days/month × 3 months) could be useful in patients (n = 16) with progressive external ophthalmoplegia (PEO). RESULTS: Our results do not formally support any effect of tetracycline on eye motility in PEO. However, some possible protective effects could not be completely ruled out, i.e. a further analysis suggests a possible difference between the tetracycline group and the placebo group, significant at least for oblique motility, when comparing the ratio between the end of the double-blind phase and baseline. Tetracycline could modify some oxidative stress biomarkers in patients with PEO. CONCLUSIONS: Further studies are needed to confirm such effects of tetracycline in patients with PEO, if any, and to clarify the mechanisms of action for antioxidant effects of tetracyclines in mitochondrial disorders and other diseases.


Assuntos
Fármacos Neuroprotetores/uso terapêutico , Oftalmoplegia Externa Progressiva Crônica/tratamento farmacológico , Tetraciclina/uso terapêutico , Adulto , Idoso , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estresse Oxidativo/efeitos dos fármacos , Projetos Piloto
4.
Rev Sci Instrum ; 92(5): 054504, 2021 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-34243263

RESUMO

In the last few decades, much effort has been made for the production of squeezed vacuum states in order to reduce quantum noise in the audio-frequency band. This technique has been implemented in all running gravitational-wave interferometric detectors and helped to improve their sensitivity. While the detectors are acquiring data for astrophysical observations, they must be kept in the operating condition, also called "science mode," that is, a state that requires the highest possible duty-cycle for all the instrumental parts and controls. We report the development of a highly automated setup for the generation of optical squeezed states, where all the required control loops are supervised by a software based on finite state machines; we took special care to grant ease of use, stability of operation, and possibility of auto-recovery. Moreover, the setup has been designed to be compatible with the existing software and hardware infrastructure of the Virgo detector. In this paper, we discuss the optical properties of this squeezing setup, the locking techniques, and the automation algorithms.

5.
Oncogene ; 26(46): 6604-18, 2007 Oct 11.
Artigo em Inglês | MEDLINE | ID: mdl-17471235

RESUMO

CD99 gene encodes two distinct proteins, produced by alternative splicing of CD99 gene transcript. Full-length CD99 isoform (CD99wt) is formed by an extracellular domain, followed by a transmembrane domain and a 36 amino-acid intracytoplasmic domain, which is partially deleted in the truncated, short form (CD99sh). A differential expression of these two CD99 molecules can lead to distinct functional outcomes in lymphocytes. To investigate the functional effects of CD99 molecules on malignancy, forced overexpression of the two CD99 isoforms was induced in osteosarcoma and prostate cancer cells. The two isoforms exhibited opposite functions: the major form dramatically inhibits anchorage-independent growth, anoikis resistance, migration and metastasis, whereas the CD99sh remarkably favours the phenomena. A mechanistic analysis of CD99-transfected osteosarcoma cells points to involvement of c-Src family kinase activity in regulating CD99 functions in malignancy. Ser168 residue of CD99 plays a pivotal role in the reversion of the malignant phenotype. Our findings highlight the involvement of CD99 in crucial processes of cancer malignancy, serving as a curtain raiser for this, so far neglected molecule. In addition, a dualistic role for the two CD99 isoforms was shown in agreement with what was observed for other cell adhesion molecules.


Assuntos
Antígenos CD/fisiologia , Moléculas de Adesão Celular/fisiologia , Transformação Celular Neoplásica , Metástase Neoplásica , Neoplasias/metabolismo , Proteínas Tirosina Quinases/fisiologia , Antígeno 12E7 , Proteína Tirosina Quinase CSK , Regulação Neoplásica da Expressão Gênica , Genes src , Humanos , Masculino , Osteossarcoma/metabolismo , Neoplasias da Próstata/metabolismo , Isoformas de Proteínas/fisiologia , Transfecção , Células Tumorais Cultivadas , Quinases da Família src
6.
Cytogenet Genome Res ; 121(3-4): 196-200, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18758159

RESUMO

The mammalian chromosomes present specific sites of gaps or breaks, the common fragile sites (CFSs), when the cells are exposed to DNA replication stress or to some DNA binding compounds. CFSs span hundreds or thousands of kilobases. The analysis of these sequences has not definitively clarified the causes of their fragility. There is considerable evidence that CFSs are regions of late or slowed replication in the presence of sequence elements that have the propensity to form secondary structures, and that the cytogenetic expression of CFSs may be due to unreplicated DNA. In order to analyse the relationship between DNA replication time and fragility, in this work we have investigated the timing of replication of sequences mapping within two CFSs (FRA1H and FRA2G), of syntenic non-fragile sequences and of early and late replicating control sequences by using fluorescent in situ hybridization on interphase nuclei, conventional fluorescence microscopy and confocal microscopy. Our results indicate that the fragile sequences are slow replicating and that they enter G2 phase unreplicated with very high frequency. Thus these regions could sometimes reach mitosis unreplicated or undercondensed and be expressed as chromosome gaps/breakages.


Assuntos
Sítios Frágeis do Cromossomo , Replicação do DNA , Células Cultivadas , Cromossomos Artificiais Bacterianos , Humanos , Hibridização in Situ Fluorescente , Microscopia Confocal , Microscopia de Fluorescência
7.
Mol Neurobiol ; 55(6): 4959-4972, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28786015

RESUMO

Homeostatic plasticity is a regulatory feedback response in which either synaptic strength or intrinsic excitability can be adjusted up or down to offset sustained changes in neuronal activity. Although a growing number of evidences constantly provide new insights into these two apparently distinct homeostatic processes, a unified molecular model remains unknown. We recently demonstrated that REST is a transcriptional repressor critical for the downscaling of intrinsic excitability in cultured hippocampal neurons subjected to prolonged elevation of electrical activity. Here, we report that, in the same experimental system, REST also participates in synaptic homeostasis by reducing the strength of excitatory synapses by specifically acting at the presynaptic level. Indeed, chronic hyperactivity triggers a REST-dependent decrease of the size of synaptic vesicle pools through the transcriptional and translational repression of specific presynaptic REST target genes. Together with our previous report, the data identify REST as a fundamental molecular player for neuronal homeostasis able to downscale simultaneously both intrinsic excitability and presynaptic efficiency in response to elevated neuronal activity. This experimental evidence adds new insights to the complex activity-dependent transcriptional regulation of the homeostatic plasticity processes mediated by REST.


Assuntos
Hipocampo/metabolismo , Homeostase/fisiologia , Plasticidade Neuronal/fisiologia , Neurônios/metabolismo , Terminações Pré-Sinápticas/fisiologia , Proteínas Repressoras/metabolismo , Animais , Camundongos , Proteínas Repressoras/genética , Vesículas Sinápticas/metabolismo
8.
Mol Neurobiol ; 55(12): 8788-8798, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29600349

RESUMO

Biopolymers are increasingly employed for neuroscience applications as scaffolds to drive and promote neural regrowth, thanks to their ability to mediate the upload and subsequent release of active molecules and drugs. Synthetic degradable polymers are characterized by different responses ranging from tunable distension or shrinkage to total dissolution, depending on the function they are designed for. In this paper we present a biocompatible microfabricated poly-ε-caprolactone (PCL) scaffold for primary neuron growth and maturation that has been optimized for the in vitro controlled release of brain-derived neurotrophic factor (BDNF). We demonstrate that the designed morphology confers to these devices an enhanced drug delivery capability with respect to monolithic unstructured supports. After incubation with BDNF, micropillared PCL devices progressively release the neurotrophin over 21 days in vitro. Moreover, the bioactivity of released BDNF is confirmed using primary neuronal cultures, where it mediates a consistent activation of BDNF signaling cascades, increased synaptic density, and neuronal survival. These results provide the proof-of-principle on the fabrication process of micropatterned PCL devices, which represent a promising therapeutic option to enhance neuronal regeneration after lesion and for neural tissue engineering and prosthetics.


Assuntos
Materiais Biocompatíveis/química , Fator Neurotrófico Derivado do Encéfalo/administração & dosagem , Sistemas de Liberação de Medicamentos , Regeneração Nervosa , Tecido Nervoso/fisiologia , Polímeros/química , Engenharia Tecidual/métodos , Alicerces Teciduais/química , Animais , Astrócitos/citologia , Astrócitos/ultraestrutura , Biomarcadores/metabolismo , Adesão Celular , Sobrevivência Celular , Células Cultivadas , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Camundongos Endogâmicos C57BL , Neurônios/citologia , Neurônios/ultraestrutura , Poliésteres/química , Transdução de Sinais , Sinapses/metabolismo
10.
J Alzheimers Dis ; 10(4): 371-8, 2006 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17183148

RESUMO

Patients with Alzheimer disease (AD) often exhibit psychiatric symptoms associated with cognitive impairment. The serotoninergic system may be involved in the development of depressive symptoms in AD patients, as suggested by the evidence that antidepressant drugs having the serotonin transporter as their target are effectively used to treat depressive AD patients. The aim of this study was to investigate the role of serotonin in depression, searching for association of two serotoninergic polymorphisms (T102C of serotonin receptor 5-HT2A and serotonin transporter linked polymorphic region -5-HTTLPR- of SLC6A4 gene) with depressive symptoms and considering their possible interactions with Apolipoprotein E (ApoE) and between themselves, in a sample of 208 sporadic AD patients and 116 normal controls from Italy. 5-HTTLPR and T102C are not associated with AD when separately analysed. However, we found out an interaction between the two polymorphisms in L/L and C/C genotype carriers increasing the risk for the disease (p=0.015, OR=8.048; 95% CI: 1.497-43.262). No association of the polymorphisms was detected with depression linked to AD. No interaction between 5-HTTLPR and T102C was detected in depressive AD subjects, even after stratification according to the presence of ApoE4 allele. These results suggest that the serotoninergic system may be not involved in the pathogenesis of depressive symptoms in AD patients, and it may be involved in other aspects of disease pathophysiology like cognitive symptoms and psychosis.


Assuntos
Alelos , Doença de Alzheimer/genética , Transtorno Depressivo/genética , Polimorfismo Genético/genética , Receptor 5-HT2A de Serotonina/genética , Proteínas da Membrana Plasmática de Transporte de Serotonina/genética , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/diagnóstico , Apolipoproteína E4/genética , Transtorno Depressivo/diagnóstico , Feminino , Triagem de Portadores Genéticos , Genótipo , Humanos , Masculino , Fatores de Risco
11.
Genet Test ; 9(1): 30-6, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15857184

RESUMO

Facioscapulohumeral muscular dystrophy type 1A (FSHD1A) is an autosomal dominant inherited disorder characterized by early involvement of facial and scapular muscles with eventual spreading to pelvic and lower limb muscles. A high degree of clinical variability with respect to age at onset, severity, and pattern of muscle involvement, both between and within families, is present. For this reason, diagnosis of FSHD1A can be sometimes difficult and molecular diagnosis is then necessary. A clinical and molecular genetic-based epidemiological investigation has been carried out in the territory of northwestern Tuscany in central Italy to calculate the prevalence rate of FSHD1A as of March, 2004. The molecular diagnosis has been based on the detection of large deletions of variable size of kpnI repeat units on chromosome 4q35. Results have been compared to those of a previous study conducted in the same area in 1981 (in the premolecular diagnosis era). The minimum prevalence rate was 4.60 x 10(-5) inhabitants, a value four times higher compared to our previous study. No significant correlation between fragment size and clinical severity has been observed. This study confirms in an Italian population a prevalence rate of FSHD1A similar to that observed in other populations. Furthermore, it underlines the usefulness of routine adoption of the genetic testing in confirming clinical suspicion of FSHD1A as well as in correctly diagnosing atypical and otherwise misclassified cases.


Assuntos
Distrofia Muscular Facioescapuloumeral/genética , Adolescente , Adulto , Idoso , Criança , Genótipo , Humanos , Itália/epidemiologia , Pessoa de Meia-Idade , Distrofia Muscular Facioescapuloumeral/epidemiologia , Fenótipo
12.
Int J Oncol ; 1(4): 443-50, 1992 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21584565

RESUMO

Nausea and vomiting remain important clinical problems occuring in 25 to 50% of patients receiving chemotherapy for cancer. Clinical trials comparing a new antiemetic drug, ondansetron, to metoclopramide have suggested improved control of nausea and vomiting but studies disagree on the magnitude of the treatment effect and its statistical significance. We combined evidence from randomized controlled trials in a meta-analysis of the efficacy and safety of ondansetron compared to metoclopramide in the prevention of acute (less-than-or-equal-to 24 hours) nausea and emesis associated with chemotherapy. Literature search identified six randomised controlled trials of ondansetron versus metoclopramide in an adult population. Study outcomes were the observed incidence of emesis (vomiting or retching) and patient-reponed grades of nausea after chemotherapy. For meta-analysis of each outcome we defined therapeutic success as complete protection (ie. zero episodes during 24 hours following chemotherapy). The relative odds of success (ondansetron/metoclopramide) was calculated for each trial and all trials combined. Results were expressed as a relative risk (RR) for zero emesis or nausea at 24 hours. The six trials reported on 705 patients (median age range 53-59 years; 57% female). Relative odds for complete control of emesis was greater than one in all trials but was nonsignificant (p>0.05) in two trials, including the largest trial. When trials were combined, summary odds ratios for control of emesis and nausea were greater than one (p<0.05). RR of zero emesis with ondansetron was 1.72 (95% CI 1.45 to 1.97) and was similar for nausea (RR= 1.78, 95% CI 1.39 to 2.13). In trials using high-dose cisplatin chemotherapy, higher rates of extrapyramidal affects and diarrhea were associated with metoclopramide (p<0.05) while headache was frequently associated with ondansetron (p<0.05). Combined clinical trial evidence supports the conclusion. that, relative to metoclopramide, ondansetron places patients at a much lower risk of nausea and emesis following chemotherapy with moderately or highly emetogenic regimens.

13.
Brain Res Bull ; 61(1): 1-24, 2003 Jun 30.
Artigo em Inglês | MEDLINE | ID: mdl-12788204

RESUMO

Alzheimer's disease (AD) is the most common type of dementia in the elderly population. Three genes have been identified as responsible for the rare early-onset familial form of the disease: the amyloid precursor protein (APP) gene, the presenilin 1 (PSEN1) gene and the presenilin 2 (PSEN2) gene. Mutations in these genes, however, account for less than 5% of the total number of AD cases. The remaining 95% of AD patients are mostly sporadic late-onset cases, with a complex aetiology due to interactions between environmental conditions and genetic features of the individual. In this paper, we review the most important genes supposed to be involved in the pathogenesis of AD, known as susceptibility genes, in an attempt to provide a comprehensive picture of what is known about the genetic mechanisms underlying the onset and progression of AD. Hypotheses about the role of each gene in the pathogenic pathway are discussed, taking into account the functions and molecular features, if known, of the coded protein. A major susceptibility gene, the apolipoprotein E (APOE) gene, found to be associated with sporadic late-onset AD cases and the only one, whose role in AD has been confirmed in numerous studies, will be included in a specific chapter. As the results reported by association studies are conflicting, we conclude that a better understanding of the complex aetiology that underlies AD may be achieved likely through a multidisciplinary approach that combines clinical and neurophysiological characterization of AD subtypes and in vivo functional brain imaging studies with molecular investigations of genetic components.


Assuntos
Doença de Alzheimer/genética , Predisposição Genética para Doença , Doença de Alzheimer/epidemiologia , Precursor de Proteína beta-Amiloide/genética , Animais , Apolipoproteínas E/sangue , Causalidade , Humanos , Proteínas de Membrana/genética , Polimorfismo Genético , Presenilina-1 , Fatores de Risco
14.
Brain Res Bull ; 56(3-4): 405-10, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11719279

RESUMO

Steinert's myotonic dystrophy (DM) is a genetic autosomal dominant disease and the most frequent muscular dystrophy in adulthood. Although causative mutation is recognized as a CTG trinucleotide expansion on 19q13.3, pathogenic mechanisms of multisystem involvement of DM are still under debate. It has been suggested that mitochondrial abnormalities can occur in this disease and deficiency of coenzyme Q 10 (CoQ10) has been considered one possible cause for this. The aim of this investigation was to evaluate, in 35 DM patients, CoQ10 blood levels and relate them to the degree of CTG expansion as well as to the amount of lactate production in exercising muscle as indicator of mitochondrial dysfunction. CoQ10 concentrations appeared significantly reduced with respect to normal controls: 0.85 +/- 0.25 vs. 1.58 +/- 0.28 microg/ml (p < 0.05). Mean values of blood lactate were significantly higher in DM patients than controls (p < 0.05) both in resting conditions (2.9 +/- 0.55 vs. 1.44 +/- 1.11 mmol/L) and at the exercise peak (6.77 +/- 1.79 vs. 4.90 +/- 0.59 mmol/L), while exercise lactate threshold was anticipated (30-50% vs. 60-70% of the predicted normal maximal power output, p < 0.05). Statistical analysis showed that serum CoQ10 levels were significantly (p < 0.05) inversely correlated with both CTG expansion degree and lactate values at exercise lactate threshold level. Our data indicates the occurrence of reduced CoQ10 levels in DM, possibly related to disease pathogenic mechanisms associated with abnormal CTG trinucleotide amplification.


Assuntos
Ácido Láctico/sangue , Distrofia Miotônica/sangue , Distrofia Miotônica/genética , Expansão das Repetições de Trinucleotídeos , Ubiquinona/análogos & derivados , Ubiquinona/sangue , Adulto , Criança , Coenzimas , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mitocôndrias/metabolismo , Fenótipo , Esforço Físico , Valor Preditivo dos Testes , Ubiquinona/metabolismo
15.
Mutat Res ; 282(1): 43-8, 1992 May.
Artigo em Inglês | MEDLINE | ID: mdl-1374157

RESUMO

DAPI is a non-intercalating compound which binds specifically to the AT bases of DNA. When leukocytes are grown in complete medium (RPMI 1640) DAPI induces the expression of three fragile sites on human chromosomes and if the medium is deficient in folic acid and thymidine (199M) it induces 19 fragile sites. Caffeine has been found by different authors to considerably enhance the expression of chromosome breaks which have been produced by other agents. When it is added to the complete medium after DAPI, it elicits almost all the sites that DAPI only induces in incomplete medium. When caffeine is added after DAPI to incomplete medium, it does not significantly or unidirectionally modify the capacity of the two subjects examined to elicit fragile sites. The analysis of these results, when correlated with that of the mitotic index, reveals a different sensitivity of the two subjects to the combined DAPI-caffeine treatment. The results are quite compatible with the hypothesis that the DAPI-induced fragile sites are DNA regions which are not accurately replicated during the S phase.


Assuntos
Cafeína/toxicidade , Fragilidade Cromossômica , Indóis/toxicidade , Mutagênicos/toxicidade , Células Cultivadas , Distribuição de Qui-Quadrado , Sítios Frágeis do Cromossomo , Interações Medicamentosas , Feminino , Humanos , Masculino
16.
Genet Test ; 7(4): 309-14, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-15000807

RESUMO

Patients with Alzheimer disease (AD) often exhibit psychotic symptoms associated with cognitive impairment. A few association studies have been carried out to determine if the serotonin transporter and receptor genes are potential risk factors for AD and/or associated psychopathology. The aim of this study was to investigate the association of a serotonin transporter gene-linked polymorphic region (5-HTTLPR) and the 5-HT2A receptor T102C polymorphism with the risk of developing dementia and/or psychotic symptoms in a group of sporadic AD patients from Italy. No significant differences in the distribution of allele and genotype frequencies of 5-HTTLPR and 5-HT2A T102C were found between patient and control groups. However, a significant association between the C102/C102 5-HT2A genotype and psychotic symptoms (p < 0.001) was observed. Our data strongly confirm results from previous studies suggesting that the C102 allele of the 5-HT2A receptor is associated with the occurrence of psychotic symptoms in AD. On the contrary, the serotonin transporter does not appear to be a major susceptibility factor in the pathophysiology of the disease.


Assuntos
Doença de Alzheimer/complicações , Proteínas de Transporte/genética , Glicoproteínas de Membrana/genética , Proteínas de Membrana Transportadoras , Proteínas do Tecido Nervoso/genética , Polimorfismo Genético , Transtornos Psicóticos/genética , Receptor 5-HT2A de Serotonina/genética , Idoso , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/genética , Apolipoproteínas E/genética , Estudos de Casos e Controles , Feminino , Predisposição Genética para Doença , Humanos , Itália , Masculino , Transtornos Psicóticos/etiologia , Serotonina/genética , Proteínas da Membrana Plasmática de Transporte de Serotonina
17.
J Dent ; 29(3): 173-9, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11306158

RESUMO

OBJECTIVES: Dentinal hypersensitivity and recurrent disease may necessitate the use of anaesthetic during periodontal recall visits. However, an aversion to injections may affect patient compliance. The objectives of this study were to determine choices patients and 'potential' patients make when provided with information on the risks and benefits of alternative anaesthetic choices for root planing during periodontal recalls and to examine which factors influence these choices. METHODS: Using an interactive computer tool, scenarios described the risks and benefits of root planing during periodontal maintenance and the anaesthetic alternatives (no anaesthetic, an experimental thermosetting gel anaesthetic and traditional local infiltration anaesthesia). Compliant patients for whom anaesthesia was recommended during recall cleanings were recruited from private periodontal practices (n=97). General population subjects (potential patients) were recruited by random digit dialing (n=196) RESULTS: As dental insurance was one of the inclusion criteria, the sample was representative of a working population. Most subjects reported tooth sensitivity (recall 84.5%, general 59.9%). The majority of patients wanted some form of anaesthetic, either gel (recall 82.5%, general 81.0%) or local infiltration (recall 10.3%, general 16.4%). Fifty-five percent of subjects reported moderate or severe pain from their previous dental injection(s). Asked if they were to have a dental needle tomorrow, 52.5% would be somewhat or very anxious. Of those who chose gel, 63.47% would be more or much more willing to return for recall visits if the gel were available. Using multivariate logistic regression, concern about pain and anxiety associated with needles were the only statistically significant characteristics associated with anaesthetic preference. CONCLUSIONS: Concern about pain and anxiety associated with needles dominates preferences for dental anaesthesia. The overwhelming preference for a non-injectable anaesthetic reveals a strong clinical need for such alternatives.


Assuntos
Anestesia Dentária , Anestésicos Locais/administração & dosagem , Atitude Frente a Saúde , Comportamento de Escolha , Doenças Periodontais/terapia , Administração Tópica , Adulto , Ansiedade ao Tratamento Odontológico/psicologia , Raspagem Dentária , Sensibilidade da Dentina/terapia , Feminino , Géis , Humanos , Injeções/instrumentação , Injeções/psicologia , Lidocaína/administração & dosagem , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Agulhas , Dor/psicologia , Cooperação do Paciente , Satisfação do Paciente , Doenças Periodontais/prevenção & controle , Prilocaína/administração & dosagem , Recidiva , Medição de Risco , Aplainamento Radicular , Interface Usuário-Computador
18.
Minerva Med ; 81(10): 679-82, 1990 Oct.
Artigo em Italiano | MEDLINE | ID: mdl-2234460

RESUMO

Twenty-nine patients who had received chronic hemodialysis for more than 5 years provided the material for the present study. In 12 of them (41%) there were radiological findings of dialysis related amyloidosis, mainly destructive spondyloarthropathy of the cervical spine (n = 11) and geodes of the shoulder (n = 5). When compared with negative patients, these patients were significantly older (p less than 0.001 and had been dialyzed for longer periods of time (p less than 0.01). Moreover, in such patients there was an higher incidence of carpal tunnel syndrome (p less than 0.025) and shoulder pain (p less than 0.001). Our results confirm that osteoarticular amyloidosis is a frequent long-term complication of chronic hemodialysis and underline the correlation between clinical and radiological findings.


Assuntos
Amiloidose/diagnóstico por imagem , Artropatias/diagnóstico por imagem , Sistema Linfático , Diálise Renal/efeitos adversos , Osteofitose Vertebral/diagnóstico por imagem , Adulto , Idoso , Amiloidose/complicações , Amiloidose/etiologia , Dilatação Patológica/diagnóstico por imagem , Feminino , Humanos , Artropatias/etiologia , Masculino , Pessoa de Meia-Idade , Radiografia , Osteofitose Vertebral/complicações , Osteofitose Vertebral/etiologia
19.
Curr Mol Med ; 14(5): 598-602, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24894177

RESUMO

Kennedy disease (spinal and bulbar muscular atrophy, or SBMA) is a motor neuron disease caused by a CAG expansion in the androgen-receptor (AR) gene. Increasing evidence shows that SBMA may have a primary myopathic component and that mitochondrial dysfunction may have some role in the pathogenesis of this disease. In this article, we review the role of mitochondrial dysfunction and of the mitochondrial genome (mtDNA) in SBMA, and we present the illustrative case of a patient who presented with increased CK levels and exercise intolerance. Molecular analysis led to definitive diagnosis of SBMA, whereas muscle biopsy showed a mixed myopathic and neurogenic process with "mitochondrial features" and multiple mtDNA deletions, supporting some role of mitochondria in the pathogenesis of the myopathic component of Kennedy disease. Furthermore, we briefly review the role of mitochondrial dysfunction in two other motor neuron diseases (namely spinal muscular atrophy and amyotrophic lateral sclerosis). Most likely, in most cases mtDNA does not play a primary role and it is involved subsequently. MtDNA deletions may contribute to the neurodegenerative process, but the exact mechanisms are still unclear. It will be important to develop a better understanding of the role of mitochondrial dysfunction in motoneuron diseases, since it may lead to the development of more effective strategies for the treatment of this devastating disorder.


Assuntos
Atrofia Bulboespinal Ligada ao X/metabolismo , Atrofia Bulboespinal Ligada ao X/fisiopatologia , Doença dos Neurônios Motores/metabolismo , Doença dos Neurônios Motores/fisiopatologia , Animais , Atrofia Bulboespinal Ligada ao X/genética , DNA Mitocondrial/genética , Humanos , Mitocôndrias/metabolismo , Mitocôndrias/patologia , Doença dos Neurônios Motores/genética , Receptores Androgênicos/genética
20.
Free Radic Res ; 47(8): 569-76, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23668794

RESUMO

A number of evidences indicates oxidative stress as a relevant pathogenic factor in Alzheimer's disease (AD) and mild cognitive impairment (MCI). Considering its recognized major genetic risk factors in AD, apolipoprotein (APO E) has been investigated in several experimental settings regarding its role in the process of reactive oxygen species (ROS) generation. The aim of this work has been to evaluate possible relationships between APO E genotype and plasma levels of selected oxidative stress markers in both AD and MCI patients. APO E genotypes were determined using restriction enzyme analysis. Plasma levels of oxidative markers, advanced oxidation protein products, iron-reducing ability of plasma and, in MCI, activity of superoxide dismutases were evaluated using spectrophotometric analysis. We found, compared to controls, increased levels of oxidized proteins and decreased values of plasma-reducing capacity in both AD patients (p < 0.0001) and MCI patients (p < 0.001); the difference between AD and MCI patients was significant only for plasma-reducing capacity (p < 0.0001), the former showing the lowest values. Superoxide dismutase activity was reduced, although not at statistical level, in MCI compared with that in controls. E4 allele was statistically associated (p < 0.05) with AD patients. When comparing different APO E genotype subgroups, no difference was present, as far as advanced oxidation protein products and iron-reducing ability of plasma levels were concerned, between E4 and non-E4 carriers, in both AD and MCI; on the contrary, E4 carriers MCI patients showed significantly decreased (p < 0.05) superoxide dismutase activity with respect to non-E4 carriers. This study, in confirming the occurrence of oxidative stress in AD and MCI patients, shows how it can be related, at least for superoxide dismutase activity in MCI, to APO E4 allele risk factor.


Assuntos
Doença de Alzheimer/genética , Apolipoproteínas E/genética , Disfunção Cognitiva/genética , Estresse Oxidativo , Polimorfismo Genético/genética , Idoso , Idoso de 80 Anos ou mais , Alelos , Doença de Alzheimer/sangue , Doença de Alzheimer/metabolismo , Apolipoproteínas E/sangue , Apolipoproteínas E/metabolismo , Disfunção Cognitiva/sangue , Disfunção Cognitiva/metabolismo , Feminino , Genótipo , Humanos , Masculino , Fatores de Risco , Superóxido Dismutase/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA